Traws Pharma to resubmit influenza drug data to MHRA in Q3 2026
Traws Pharma announced it will resubmit an updated toxicology data package for tivoxavir marboxil to the UK's MHRA in Q3 2026 to advance a Phase 2a human influenza challenge study. The regulatory progress is material for the clinical-stage biotech's lead antiviral program targeting seasonal influenza and other viral threats.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day